ClinicalTrials.gg
RecruitingNCT07261475ZAFRANUpdated Feb 4, 2026

Crocus Sativus Tepals Water Extract in Obesity and Prediabetes

An Early Phase 1 interventional study of Crocus sativus tepals cold aqueous extract and cold water in Prediabetes and Obesity & Overweight, sponsored by University of Primorska. Recruiting at 1 site in Slovenia. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by University of Primorska · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to determine the acute effects of ingestion of a cold aqueous extract of Crocus sativus tepals on postprandial glycemia and other indicators of metabolic health in patients with obesity and/or prediabetes. The main questions it aims to answer are:

  • Does the ingestion of Crocus sativus tepals cold aqueous extract prior to a meal improve the glycemic response to a standard meal?
  • How does the ingestion of Crocus sativus tepals aqueous extract prior to a meal impact insulin levels and other markers of metabolic health?
  • Does the ingestion of Crocus sativus tepals cold aqueous extract prior to a meal increase the resting energy expanditure?

Researchers will compare Crocus sativus tepals cold aqueous extract to cold water.

The participants will visit the Faculty twice - on one visit they will ingest Crocus sativus tepals cold aqueous extract and on the other cold water (in random order) 5 minutes prior to a standard meal of 100 g of white bread.

On each visit, anthropometric measurements will be performed upon arrival. Blood samples will be collected 3 times, preceeded by resting metabolic rate and blood pressure measurements: at baseline in fasted conditions, and 60 minutes and 120 minutes after consuming the bread.

There will be an at least 7 days wash-out period between the two visits.

02

Conditions studied

  • Prediabetes
  • Obesity & Overweight

Keywords

  • Crocus sativus tepals
  • Glycaemia
  • Oral glucose tolerance test
  • resting metabolism
  • blood pressure
  • insulin
03

In context

Prediabetic State

918 studies on the registry are indexed under Prediabetic State; 232 are open to participants now.

This study's planned enrollment of 20 is below the median of 62 across 762 interventional studies indexed under Prediabetic State.

Browse Prediabetic State studies →

Lead sponsor

University of Primorska is the lead sponsor of 56 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Obesity type I (ITM > 30 kg/m2) and/or
  • Prediabetes (fasting glucose levels 6,1 - 6,9 mmol/L)

Exclusion criteria

Exclusion Criteria:

  • Gastrointestinal diseases
  • Diabetes mellitus of any type
  • Pregnant or lactating, without
  • Serious clinical conditions such as cancer, severe infections, severe psychiatric disorders, diseases, inflammatory diseases
  • Participation in another clinical trial 3 months prior to the study
  • ITM greater than 35 kg/m2
  • Celiac disease of gluten intolerance
  • electronic implant
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Crocus sativus

    Crocus sativus tepals cold aqueous extract

    Biological: Crocus sativus tepals cold aqueous extract

  • Sham comparator
    water

    cold water

    Biological: cold water

Interventions

  • BiologicalCrocus sativus tepals cold aqueous extract

    2 g of Crocus sativus tepals will be infused in 200 mL of water overnight at 4 °C, resulting cold aqueous extract corresponds to 40 mg GAE of polyphenols

  • Biologicalcold water

    200 mL of cold water, kept overnight at 4 °C

06

What researchers measure

Primary outcomes

  1. glucose levels

    Serum glucose levels will be measured from venous blood at baseline and 60 and 120 minutes after bread ingestion.

    Time frame: From enrollment to the end of second measurement at 2 weeks

Secondary outcomes

  1. insulin level

    Serum insulin levels will be measured from venous blood at baseline and 60 and 120 minutes after bread ingestion.

    Time frame: From enrollment to the end of second measurement at 2 weeks.

  2. Resting metabolism

    Resting metabolism will be measured with indirect calorimetry at baseline in fasted state and at 40 and 100 minutes after bread ingestion. To determine RMR, subjects will lie relaxed on a bed in a thermoneutral room for 10 minutes to calm down, followed by a 20-minute measurement of oxygen consumption (VO2) and carbon dioxide production (VCO2). RMR and RQ will be calculated from stable values over a 15-minute period (the first 5 minutes of measurement until stabilization will not be taken into account).

    Time frame: From enrollment to the end of the second measurement, at 2 weeks

  3. Blood pressure

    Time frame: baseline, 60 minutes after bread ingestion, 120 minutes after bread ingestion

07

Study locations

1 of 1 sites recruiting
  • University pf Primorska, Faculty of Health Sciences
    Izola, 6310, Slovenia
    Recruiting
    • Nina Mohorko, PhD · Contactnina.mohorko@fvz.upr.si · +386 5 66 35 818
    • Ana Petelin, PhD · Contactana.petelin@fvz.upr.si · +386 5 66 26 469
    • Nina Mohorko, PhD · Principal investigator
    • Zala Jenko Pražnikar, PhD · Sub investigator
    • Ana Petelin, PhD · Sub investigator
    • Bernarda Habe · Sub investigator
    • Tanja Črešnovar · Sub investigator
08

References and documents

Publications

  • Barik SK, Sengupta S, Arya R, Kumar S, Kim JJ, Chaurasia R. Dietary Polyphenols as Potential Therapeutic Agents in Type 2 Diabetes Management: Advances and Opportunities. Adv Nutr. 2025 Jan;16(1):100346. doi: 10.1016/j.advnut.2024.100346. Epub 2024 Nov 19. PubMed 39566886 ↗
  • Omidi A, Riahinia N, Montazer Torbati MB, Behdani MA. Hepatoprotective effect of Crocus sativus (saffron) petals extract against acetaminophen toxicity in male Wistar rats. Avicenna J Phytomed. 2014 Sep;4(5):330-6. PubMed 25386395 ↗
  • Moratalla-Lopez N, Bagur MJ, Lorenzo C, Salinas MEMR, Alonso GL. Bioactivity and Bioavailability of the Major Metabolites of Crocus sativus L. Flower. Molecules. 2019 Aug 2;24(15):2827. doi: 10.3390/molecules24152827. PubMed 31382514 ↗
  • Montoro P, Maldini M, Luciani L, Tuberoso CI, Congiu F, Pizza C. Radical scavenging activity and LC-MS metabolic profiling of petals, stamens, and flowers of Crocus sativus L. J Food Sci. 2012 Aug;77(8):C893-900. doi: 10.1111/j.1750-3841.2012.02803.x. Epub 2012 Jul 18. PubMed 22809329 ↗
  • Menghini L, Leporini L, Vecchiotti G, Locatelli M, Carradori S, Ferrante C, Zengin G, Recinella L, Chiavaroli A, Leone S, Brunetti L, Orlando G. Crocus sativus L. stigmas and byproducts: Qualitative fingerprint, antioxidant potentials and enzyme inhibitory activities. Food Res Int. 2018 Jul;109:91-98. doi: 10.1016/j.foodres.2018.04.028. Epub 2018 Apr 16. PubMed 29803496 ↗
  • Bursac B, Bellachioma L, Gligorovska L, Jovanovic M, Teofilovic A, Vrataric M, Vojnovic Milutinovic D, Albacete A, Martinez-Melgarejo PA, Morresi C, Damiani E, Bacchetti T, Djordjevic A. Crocus sativus tepals extract suppresses subcutaneous adipose tissue hypertrophy and improves systemic insulin sensitivity in mice on high-fat diet. Biofactors. 2024 Jul-Aug;50(4):828-844. doi: 10.1002/biof.2043. Epub 2024 Feb 6. PubMed 38318672 ↗
  • Bellachioma L, Morresi C, Albacete A, Martinez-Melgarejo PA, Ferretti G, Giorgini G, Galeazzi R, Damiani E, Bacchetti T. Insights on the Hypoglycemic Potential of Crocus sativus Tepal Polyphenols: An In Vitro and In Silico Study. Int J Mol Sci. 2023 May 24;24(11):9213. doi: 10.3390/ijms24119213. PubMed 37298165 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for Jun 2026, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2025
First posted
Dec 3, 2025
StartEst.
Feb 6, 2026
Primary completionEst.
Jun 2026
CompletionEst.
Dec 2026
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07261475
Lead sponsor
University of Primorska
Collaborators
Università Politecnica delle Marche
Responsible party
Nina Mohorko (Associate professor, University of Primorska) — Principal investigator
First posted
Dec 3, 2025
Start date
Feb 6, 2026 (estimated)
Primary completion
Jun 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 4, 2026

Study contacts

Nina Mohorko, PhD
Contact
nina.mohorko@fvz.upr.si
+386 5 66 35 818
Nina Mohorko, PhD
principal investigator · University pf Primorska, Faculty of Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion